Venture Investors to open Michigan office
The Madison venture capital firm, which recently moved into a larger space in the MGE Innovation Center in <a href="http:/...Venture Investors' early-stage fund grows to $115 million
The Madison-based venture capital firm, which raised $69 million in the initial closing, said the additional funding places Early Stage Fund IV among the largest Midwest...Investor warns of angel-venture funding gap
Payne, an entrepreneur-in-residence for the and a prominent angel investor, will be in Madison to address the June...Brazilian bio-industry should impress American investors
S...Investors raise $25 million for biodiesel plant
The $60 million plant, to be developed by North Prairie Produc...Accelrys to Present to Investors at C.E. Unterberg Emerging Growth Opportunities Conference
SAN DIEGO--(BUSINESS WIRE)--Jul 2, 2007 - Accelrys, Inc.(NASDAQ:ACCL), the leading provider of scientific businessintelligence software and services, announced today that its CFO,Rick Russo, will present at the C.E. Unterberg, Towbin EmergingGrowth Opportunities Conference in New York on July 11, 2007 at10:30 a.m. ET. The conference will take place at the MandarinOriental Hotel July 10th-12...Review of Nexavar Data Presented at ASCO 2007- Investor Conference Call on June 4, 2007
Leverkusen, Germany, May 31, 2007- Results from variousclinical studies including a pivotal Phase III trial in patientswith advanced hepatocellular carcinoma, or primary liver cancerwith Nexavar (sorafenib) tablets will be presented at the AnnualMeeting of the American Society of Clinical Oncology (ASCO) inChicago, USA from June 1 - 5, 2007. On this occasion a conference call for i...Northfield Laboratories Investor Update
EVANSTON, Ill.--(BUSINESS WIRE)--Apr 26, 2007 - NorthfieldLaboratories Inc. (Nasdaq: NFLD) announced today that its contractresearch organization has informed the Company that the report ofthe summary data from its pivotal Phase III trauma trial withPolyHeme(R), the Company's human-hemoglobin based oxygen-carryingred cell substitute, will not be complete until May. About Northfield Labora...Acorda Therapeutics to Host Analyst and Investor Reception
HAWTHORNE, N.Y.--(BUSINESS WIRE)--Apr 25, 2007 - AcordaTherapeutics, Inc.(R) (Nasdaq: ACOR) today announced that Dr.Lauren Krupp, Professor of Neurology at Stony Brook University,will present data from Acorda's Phase 3 clinical trial ofFampridine-SR in multiple sclerosis at their analyst and investorreception on May 2, 2007. This reception will follow a presentationof this data at the Ameri...